Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension

被引：0
|
作者：
Sinclair, Rodney [1 ]
Thaci, Diamant [2 ]
Vender, Ronald [3 ]
de Rie, Menno [4 ]
Conrad, Curdin [5 ]
Soung, Jennifer [6 ]
Strober, Bruce [7 ,8 ]
Wang, Maggie [9 ]
Cross, Nancy [10 ]
Deherder, Delphine [9 ]
Gomez, Natalie Nunez [11 ]
Gottlieb, Alice B. [12 ]
机构：
[1] Sinclair Dermatol, East Melbourne, Vic, Australia
[2] Univ Lubeck, Lubeck, Germany
[3] Dermatrials Res Inc, Hamilton, ON, Canada
[4] Univ Amsterdam, Dept Dermatol, Med Ctr, Amsterdam, Netherlands
[5] Lausanne Univ Hosp, Dept Dermatol, Lausanne, Switzerland
[6] Southern Calif Dermatol, Santa Ana, CA USA
[7] Yale Univ, New Haven, CT USA
[8] Cent Connecticut Dermatol Res, Cromwell, CT USA
[9] UCB Pharma, Brussels, Belgium
[10] UCB, Morrisville, NC USA
[11] UCB Pharma, Monheim, Germany
[12] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [21] Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Up to 5 Years of Follow-up
    Papp, Kim A.
    Lebwohl, Mark G.
    Puig, Lluis
    Ohtsuki, Mamitaro
    Beissert, Stefan
    Liu, Jie
    Wu, Tianshuang
    Sinvhal, Ranjeeta
    Soliman, Ahmed M.
    Chen, Michael M.
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB62 - AB62
  • [22] Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up
    Papp, K. A.
    Lebwohl, M. G.
    Puig, L.
    Ohtsuki, M.
    Beissert, S.
    Zeng, J.
    Rubant, S.
    Sinvhal, R.
    Zhao, Y.
    Soliman, A. M.
    Alperovich, G.
    Leonardi, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (06) : 1135 - 1145
  • [23] Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study
    Yamaguchi, Yukie
    Takatsu, Nobumichi
    Ootaki, Kenji
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2020, 47 (06): : 569 - 577
  • [24] Long-term efficacy and safety of risankizumab (RZB) for the treatment of moderate to-severe plaque psoriasis: Interim analysis of results from the LIMMitless open-label extension trial beyond 4 years of follow-up
    Papp, Kim A.
    Lebwohl, Mark G.
    Puig, Lluis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB77 - AB77
  • [25] Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48-144) of the BE RADIANT phase 3b trial
    Strober, Bruce
    Puig, Luis
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    Wang, Maggie
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Wiegratz, Susanne
    Paul, Carle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB21 - AB21
  • [26] Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48-144) of the BE RADIANT Phase 3b Trial
    Strober, Bruce
    Puig, Luis
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    Wang, Maggie
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Wiegratz, Susanne
    Merola, Joseph F.
    Paul, Carle
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2841 - 2844
  • [27] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the openlabel extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB146 - AB146
  • [28] Bimekizumab response is maintained through 2 years of treatment in patients with moderate-to-severe plaque psoriasis who responded after 16 weeks: results from the open-label extension of BE RADIANT
    Warren, Richard B.
    de Rie, Menno
    Feldman, Steven R.
    Gooderham, Melinda
    Eyerich, Kilian
    Spelman, Lynda
    White, Katy
    Staelens, Fabienne
    Gomez, Natalie Nunez
    Strober, Bruce
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 74 - 74
  • [29] Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study
    Paller, A.
    Becker, E.
    de Lucas, R.
    Paris, M.
    Zhang, W.
    Zhang, Z.
    Barcellona, C.
    Maes, P.
    Fiorillo, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 174 - 175
  • [30] Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study
    Paller, Amy
    Becker, Emily
    de Lucas, Raul
    Paris, Maria
    Zhang, Wendy
    Zhang, Zuoshun
    Barcellona, Claire
    Maes, Peter
    Fiorillo, Loretta
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB120 - AB120
12345